Earlier this month, the FDA approved ARS Pharmaceuticals Inc’s (NASDAQ:SPRY) neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients. ARS Pharma’s Neffy is to be an…
Continue reading...